Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Elite Pharmaceuticals ( (ELTP) ) has provided an update.
On March 3, 2025, Elite Pharmaceuticals announced the shipment of its first lot of finished product from its new FDA-approved expanded campus in Northvale, New Jersey. This new facility includes advanced packaging technology, significantly increasing the company’s production capacity and allowing it to meet projected packaging demand for the next five years. This expansion is expected to enhance Elite’s operational capabilities and strengthen its position in the pharmaceutical industry.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and distributing niche generic products, particularly oral, controlled-release drug products. The company operates a cGMP and DEA-registered facility in Northvale, NJ, and licenses some of its generic products to Prasco, LLC and TAGI Pharma.
YTD Price Performance: -10.93%
Average Trading Volume: 1,228,529
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $523.3M
Learn more about ELTP stock on TipRanks’ Stock Analysis page.